FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry. Application of antibody or its antigen-binding fragment is described binding extra domain A (ED-A) of fibronectin, conjugated with immunosuppressive or anti-inflammatory molecule, wherein above antibody includes VH domain (variable heavy chain domain) and VL domain (variable light chain domain), where VH domain contains amino acid sequences CDR1 (determining complementarity area 1), CDR2 and CDR3 of heavy chain in SEQ ID NO: 7 and VL domain contains amino acid sequences CDR1, CDR2 and CDR3 of light chain in SEQ ID NO: 8 for treating inflammatory bowel disease (IBD).
EFFECT: invention extends range of products for treating inflammatory bowel disease (IBD).
25 cl, 7 dwg
Title | Year | Author | Number |
---|---|---|---|
ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2649368C2 |
IMMUNOCYTOCINS COMBINED THERAPY | 2012 |
|
RU2628089C2 |
MYOCARDIAL INFARCTION TREATMENT USING TGF-BETA ANTAGONISTS | 2011 |
|
RU2637088C2 |
PARTNERS OF SPECIFIC BINDING WITH NGF | 2006 |
|
RU2406728C2 |
ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
TREATMENT OF CANCER, USING ANTIBODY TO SEMAPHORIN 4D IN COMBINATION WITH EPIGENETIC MODULATING AGENT | 2018 |
|
RU2783535C2 |
IL2 AND MUTANT TNF IMMUNOCONJUGATES | 2017 |
|
RU2758139C2 |
ANTIBODIES TO HER3 AND APPLICATION THEREOF | 2010 |
|
RU2560583C2 |
IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
Authors
Dates
2017-03-13—Published
2012-10-03—Filed